PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
MUMBAI, India & HYDERABAD, India: PopVax, an Indian full-stack biotechnology company…
Africa Oil Announces Third Quarter 2024 Results
VANCOUVER, BC, Nov. 13, 2024 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) –…
Floki’s Valhalla Partners with Dubai’s Mall of the Emirates for Landmark Campaign
Floki’s Valhalla Partners with Dubai’s Mall of the Emirates for Landmark Campaign - BitcoinWorld Skip…
Aker ASA: 2024 Employee Share Purchase Program
Aker ASA ("Aker") has today carried out its employee share purchase…
Stayble Therapeutics’ STA363 receives positive phase 1b results
Stayble Therapeutics AB ("Stayble" or the "Company") announces positive results from…
Gradiant’s alkaLi Sets New Standards in Direct Lithium Extraction
Boston, United States: Gradiant’s spin-out, alkaLi, is leading the direct lithium…
Form 8.3 – Anglogold Ashanti Plc
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A…
MapsPeople capital increase to be used as consideration to Point Consulting Pte. Ltd.
MapsPeople A/S - Inside Information Company Announcement No. 25-2024 Aalborg,…
The 7 Best Staking Platforms for Steady Passive Income in 2024
Of late, staking has emerged as one of the major weapons for crypto investors who…